Glucagon antagonists/inverse agonists
US6875760B2 · kind B2 · utility
35Cited by
4References
80Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 30, 2002 |
| Grant date | Apr 5, 2005 |
| Priority date | — |
| Expiry date | Aug 30, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/94
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.